The current study demonstrated that high SLC1A5 expression correlated significantly with a poor prognosis in bladder and breast cancers, renal clear-cell carcinoma, LGG, HCC, mesothelioma, and uveal melanoma. Here, SLC1A5 is linked to breast carcinoma.